Back to Trades
Total Value
$670.0K
Net $424.6K sold
Filing Date
Mar 10, 2026
2 transactions
Sales
$424.6K
2 transactions
Trade Summary
On Mar 6, 2026 through Mar 9, 2026, Mutz Christopher, HEAD OF RARE DISEASE, sold $670.0K of ANI PHARMACEUTICALS INC (ANIP) across 2 transactions. The filing covers Common Stock and reflects net selling of $424.6K. Reported prices ranged from $74.04 to $74.22. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- ANI PHARMACEUTICALS INC
- Ticker Symbol
- ANIP
- CIK
- 0001023024
Insider Information
- Name
- Mutz Christopher
- Role
- HEAD OF RARE DISEASE
- Location
- BAUDETTE, MN
Filing Details
- Filing Date
- Mar 10, 2026
- Transaction Date
- Mar 6, 2026
- Accession Number
- 0001846487-26-000012
- Form Type
- 4
- Net Trading Amount
- -$424.6K
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Mar 6, 2026 | Common Stock | 2,121 | $74.22 | Sale | $157.4K |
| Mar 7, 2026 | Common Stock | 3,314 | $74.04 | Tax Withholding | $245.4K |
| Mar 9, 2026 | Common Stock | 3,602 | $74.18 | Sale | $267.2K |
Want live alerts when Mutz Christopher trades again?
Download Insider Trades to track ANIP, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.
- (F2)The shares were sold in multiple trades at prices ranging from $73.14 to $75.00. The price reported above reflects the weighted average sales price.
- (F3)Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,476 shares of restricted stock, the grant of which was previously reported.
- (F4)The shares were sold in multiple trades at prices ranging from $73.27 to $74.81. The price reported above reflects the weighted average sales price.